Summary
Azapropazone, a new non-steroidal antiinflammatory drug, is strongly bound to human serum albumin. As revealed by Scatchard analysis, one high-affinity binding site with an association constant of about 1.2×106 M−1 and two low-affinity binding sites with association constants of about 0.05×106 M−1 were found. While the high-affinity binding site of azapropazone is clearly not identical with the diazepam or digitoxin binding sites of human serum albumin, contradictory evidence was found by optical measurements and displacement studies for the similarity of the azapropazone and the warfarin binding site of human serum albumin. At present, it is suggested that both drugs bind to different areas of the same binding site. Therefore, the pronounced effects of various disease states on the plasma protein binding of azapropazone can not be explained by a binding to an unusual binding site, but seem to be due to an extreme sensitivity of the azapropazone binding area to the putative endogenous binding inhibitors, present in the blood during those disease states.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Breuing, K. H., Gilfrich, H. J., Meinertz, T., Jähnchen, E.: Pharmacokinetics of azapropazone following single oral and intravenous doses. Arzneim. Forsch. 29, 971–972 (1979)
Brown, N. A., Jähnchen, E., Müller, W. E., Wollert, U.: Optical studies on the mechanisms of the interaction of the enantiomers of the anticoagulant drugs phenprocoumon and warfarin with human serum albumin. Mol. Pharmacol. 13, 70–79 (1977)
Fehske, K. J.: Properties of two important drug binding sites of human serum albumin. Naunyn-Schmiedeberg's Arch. Pharmacol. 308, R 24 (1979)
Fehske, K. J., Müller, W. E., Wollert, U.: The modification of the lone tryptophan residue in human serum albumin by 2-hydroxy-5-nitrobenzyl bromide. Hoppe-Seyler's Z. Physiol. Chem. 359, 709–717 (1978)
Fehske, K. J., Müller, W. E., Wollert, U.: A highly reactive tyrosine residue as part of the indole and benzodiazepine binding site of human serum albumin. Biochim. Biophys. Acta 577, 346–359 (1979a)
Fehske, K. J., Müller, W. E., Wollert, U.: Velden, L. M.: The lone tryptophan residue of human serum albumin as part of the specific warfarin binding site. Mol. Pharmacol. 16, 778–789 (1979b)
Geissler, H. E., Muschler, E., Faust-Tinnefeld, G.: Über die Bestimmung von Azapropazon aus Plasma durch direkte quantitative Dünnschichtchromatographie. Arzneim. Forsch. 27, 1713–1715 (1977)
Jähnchen, E., Blanck, K. J., Gilfrich, H. J., Meinertz, T., Breuing, K. H., Trenk, D.: Plasma protein binding of azapropazone in kidney and liver diseases. Br. J. Clin. Pharmacol., in press (1980)
Klatt, L., Koss, F. W.: Pharmakokinetische Untersuchungen mit 14C-Azapropazon-Dihydrat an der Ratte. Arzneim. Forsch. 23, 913–919 (1973)
Kober, A., Jenner, A., Sjöholm, I., Borga, O., Odar-Cederlöf, I.: Differentiated effects of liver cirrhosis on the albumin binding sites for diazepam, salicylic acid, and warfarin. Biochem. Pharmacol. 27, 2729–2735 (1978)
Lewis, R. J., Trager, W. F., Chan, K. K., Breckenridge, A., Orme, M., Roland, M., Schary, W.: Warfarin, stereochemical aspects of its metabolism and the interaction with phenylbutazone. J. Clin. Invest. 53, 1607–1617 (1974)
Maes, V., Hoebeke, J., Vercruysse, A., Kanarek, L.: Optical studies into the nature of the high-affinity binding site of human serum albumin for phenylbutazone. Mol. Pharmacol. 16, 147–153 (1979)
McElnay, J. C., D'Arcy, P. F.: Interaction between azapropazone and warfarin. Br. Med. J. 1977 I, 773–774
McElnay, J. C., D'Arcy, P. F.: The effect of azapropazone on the binding of warfarin to human serum proteins. J. Pharm. Pharmac. 30, 73 P (1978)
Miese, H., Müller, W. E., Wollert, U.: The influence of increasing albumin concentrations on the determination of the binding of sulfamethoxy-pyridazine to human and bovine serum albumin. Arch. Int. Pharmacodyn. Ther. 236, 18–26 (1978)
Müller, W. E., Wollert, U.: Influence of various drugs on the binding of L-tryptophan to human serum albumin. Res. Comm. Chem. Pathol. Pharmacol. 10, 565–568 (1975)
Müller, W. E., Wollert, U.: Human serum albumin as a silent receptor for drugs and endogenous substances. Pharmacology 19, 59–67 (1979)
Müller, W. E., Fehske, K. J., Wollert, U.: The effects of tryptophan and tyrosine modification on the drug-binding properties of human serum albumin. In: Transport by proteins (G. Blauer and H. Sund, eds.), W. de Gruyter Berlin: 1978
Pennock, B. E.: A calculator for finding binding parameters from a Scatchard plot. Anal. Biochem. 56, 306–309 (1973)
Powell-Jackson, P. R.: Interaction between azapropazone and warfarin. Br. Med. J. 1977I, 1193–1194
Sjöholm, I., Kober, A., Oder-Cederlöf, I., Borga, O.: Protein binding of drugs in uremic and normal serum: The role of endogenous binding inhibitors. Biochem. Pharmacol. 25, 1205–1213 (1976)
Sjöholm, I., Ekman, B., Kober, A., Ljungstedt-Pahlman, I., Seiving, B., Sjödin, T.: Binding of drugs to human serum albumin: XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol. Pharmacol. 16, 767–777 (1979)
Sudlow, G., Birkett, D. J., Wade, D. N.: The characterization of two specific drug binding sites on human serum albumin. Mol. Pharmacol. 11, 824–832 (1975)
Sudlow, G., Birkett, D. J., Wade, D. N.: Further characterization of specific drug binding sites on human serum albumin. Mol. Pharmacol. 12, 1052–1061 (1976)
Tillement, J. P., Lhoste, F., Giudicelli, J. F.: Disease and drug protein binding. Clin. Pharmacokin. 3, 144–154 (1978)
Wong, G. B., Sellers, E. M.: Intravascular factors affecting diazepam binding to human serum albumin. Biochem. Pharmacol. 28, 3265–3270 (1979)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fehske, K.J., Jähnchen, E., Müller, W.E. et al. Azapropazone binding to human serum albumin. Naunyn-Schmiedeberg's Arch. Pharmacol. 313, 159–163 (1980). https://doi.org/10.1007/BF00498574
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00498574